IL130255A0 - Crystal form 0 of clarithromycin - Google Patents

Crystal form 0 of clarithromycin

Info

Publication number
IL130255A0
IL130255A0 IL13025597A IL13025597A IL130255A0 IL 130255 A0 IL130255 A0 IL 130255A0 IL 13025597 A IL13025597 A IL 13025597A IL 13025597 A IL13025597 A IL 13025597A IL 130255 A0 IL130255 A0 IL 130255A0
Authority
IL
Israel
Prior art keywords
clarithromycin
crystal form
crystal
Prior art date
Application number
IL13025597A
Other languages
English (en)
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25136084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL130255(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of IL130255A0 publication Critical patent/IL130255A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL13025597A 1997-01-17 1997-12-19 Crystal form 0 of clarithromycin IL130255A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/785,623 US5945405A (en) 1997-01-17 1997-01-17 Crystal form O of clarithromycin
PCT/US1997/023607 WO1998031699A1 (en) 1997-01-17 1997-12-19 Crystal form 0 of clarithromycin

Publications (1)

Publication Number Publication Date
IL130255A0 true IL130255A0 (en) 2000-06-01

Family

ID=25136084

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13025597A IL130255A0 (en) 1997-01-17 1997-12-19 Crystal form 0 of clarithromycin

Country Status (18)

Country Link
US (1) US5945405A (xx)
EP (1) EP1077988A1 (xx)
JP (3) JP4058114B2 (xx)
KR (1) KR100567149B1 (xx)
CN (1) CN1174991C (xx)
AR (3) AR011077A1 (xx)
AU (1) AU735598B2 (xx)
BR (1) BR9714287A (xx)
CA (4) CA2419499A1 (xx)
CZ (1) CZ297433B6 (xx)
DE (1) DE97951771T1 (xx)
ES (1) ES2173058T1 (xx)
IL (1) IL130255A0 (xx)
NZ (1) NZ336073A (xx)
TR (1) TR199901578T2 (xx)
TW (1) TW574224B (xx)
WO (1) WO1998031699A1 (xx)
ZA (1) ZA98116B (xx)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945405A (en) * 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin
KR100377159B1 (ko) * 1998-09-09 2003-08-19 한미약품공업 주식회사 잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법
GB9827355D0 (en) * 1998-12-11 1999-02-03 Biochemie Sa Organic compounds
KR100322313B1 (ko) * 1999-10-21 2002-02-06 민경윤 클라리스로마이신 결정형 2의 제조방법 및 이에 사용되는 클라리스로마이신 포르메이트
US6627743B1 (en) * 1999-12-03 2003-09-30 Abbott Laboratories 6-O-methylerythromycin A crystal form III
WO2001044262A1 (en) * 1999-12-16 2001-06-21 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs and novel polymorph iv
FR2802534B1 (fr) * 1999-12-20 2002-02-01 Merial Sas Procede pour preparer et isoler la 9-deoxo-9 (z)- hydroxyiminoerythromycine a
CA2397092A1 (en) * 2000-01-11 2001-07-19 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
WO2001064224A1 (en) 2000-02-29 2001-09-07 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
KR100367981B1 (ko) * 2000-11-23 2003-01-14 한미약품공업 주식회사 클라리스로마이신 결정형 2의 제조 방법 및 이 방법에사용되는 결정성 클라리스로마이신 메실레이트 삼수화물
ATE338053T1 (de) * 2000-03-15 2006-09-15 Hanmi Pharm Ind Co Ltd Verfahren zur herstellung von clarythromycin mit nicht pharmazeutischer qualität
DE60138876D1 (de) * 2000-03-28 2009-07-16 Sandoz Ag Geschmackmaskierte granulierte teilchen
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
AU8206401A (en) * 2000-08-03 2002-02-18 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
KR100408848B1 (ko) * 2001-03-12 2003-12-06 주식회사 씨트리 클래리스로마이신의 정제방법
ES2323264T3 (es) * 2001-08-01 2009-07-10 Novartis Ag Composicion para enmascaramiento del sabor.
TW200302830A (en) * 2002-01-11 2003-08-16 Chugai Pharmaceutical Co Ltd Anhydrate/hydrate of an erythromycin derivative and processes for preparing said anhydrate/hydrate
CN100427498C (zh) * 2003-03-02 2008-10-22 王凌峰 克拉霉素a型结晶
US20040185092A1 (en) * 2003-03-18 2004-09-23 Yih Ming Hsiao Pharmaceutical preparations of omeprazole and/or clarithromycin for oral use
CA2533292C (en) 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
AU2004258949B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
EP1648418A4 (en) 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
CA2535177A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
EP1653924A4 (en) 2003-08-12 2009-09-09 Middlebrook Pharmaceuticals In ANTIBIOTICS, USE AND FORMULATION ASSOCIATED
CA2535780A1 (en) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
US8460710B2 (en) 2003-09-15 2013-06-11 Shionogi, Inc. Antibiotic product, use and formulation thereof
PL1670433T3 (pl) 2003-10-10 2013-03-29 Ferring Bv Przezskórna formulacja farmaceutyczna do zmniejszania pozostałości na skórze
CA2572292A1 (en) 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
US20060111560A1 (en) * 2004-11-01 2006-05-25 Glenmark Pharmaceuticals Limited Process for the preparation of crystalline form II of clarithromycin
WO2006125642A1 (en) * 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
US20070015719A1 (en) * 2005-07-07 2007-01-18 Elan Pharma International Limited Nanoparticulate clarithromycin formulations
WO2007036951A2 (en) * 2005-08-31 2007-04-05 Alembic Limited Process to obtain 6-o-methylerythromycin a (clarithromycin)_form ii
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
CA2646667C (en) * 2006-04-21 2014-03-11 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
DE102007016367A1 (de) 2007-04-03 2008-10-09 Grünenthal GmbH Polymorph von Clarithromycin (Form V)
US20090054634A1 (en) * 2007-08-09 2009-02-26 Vinod Kumar Kansal Process for the preparation of clarithromycin
EP2030613A1 (en) 2007-08-17 2009-03-04 Abbott GmbH & Co. KG Preparation of compositions with essentially noncrystalline embedded macrolide antibiotics
US9119769B2 (en) 2011-12-30 2015-09-01 The Curators Of The University Of Missouri Method for transforming pharmaceutical crystal forms
CN103087130B (zh) * 2013-02-06 2015-12-23 浙江国邦药业有限公司 一种克拉霉素晶型转换方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5782400A (en) 1980-11-12 1982-05-22 Taisho Pharmaceut Co Ltd Erythromycin derivative
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
JPS60214796A (ja) * 1984-04-06 1985-10-28 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシン類の製法
JPS61103890A (ja) 1984-10-26 1986-05-22 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシンａ誘導体
US4670549A (en) * 1985-03-18 1987-06-02 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin a derivatives
DE3782994T2 (de) * 1986-09-18 1993-04-08 Taisho Pharma Co Ltd Erythromycin-a-derivate und verfahren zu ihrer herstellung.
JPH0755958B2 (ja) * 1986-10-03 1995-06-14 大正製薬株式会社 エリスロマイシンａ誘導体の製造方法
JP2526951B2 (ja) * 1986-12-17 1996-08-21 大正製薬株式会社 エリスロマイシンａ誘導体およびその製造方法
KR960000434B1 (ko) 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법
US4808411A (en) * 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions
JP2751385B2 (ja) * 1988-05-19 1998-05-18 大正製薬株式会社 エリスロマイシンａオキシム及びその塩の製造方法
US5556839A (en) * 1991-04-29 1996-09-17 Eli Lilly And Company Form II Dirithromycin
US5872229A (en) 1995-11-21 1999-02-16 Abbott Laboratories Process for 6-O-alkylation of erythromycin derivatives
US5719272A (en) 1996-04-02 1998-02-17 Abbott Laboratories 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
US5837829A (en) 1996-04-02 1998-11-17 Abbott Laboratories 9-oximesilyl erythromycin a derivatives
DK0915899T3 (da) * 1996-07-29 2004-11-29 Abbott Lab Fremstilling af krystallinsk form II af clarithromycin
US5858986A (en) * 1996-07-29 1999-01-12 Abbott Laboratories Crystal form I of clarithromycin
US5945405A (en) * 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin

Also Published As

Publication number Publication date
CA2387356C (en) 2003-05-27
CN1174991C (zh) 2004-11-10
KR20000070220A (ko) 2000-11-25
CA2277274A1 (en) 1998-07-23
TW574224B (en) 2004-02-01
CA2387361C (en) 2003-05-27
KR100567149B1 (ko) 2006-04-04
ZA98116B (en) 1998-07-08
US5945405A (en) 1999-08-31
ES2173058T1 (es) 2002-10-16
AR011077A1 (es) 2000-08-02
CA2419499A1 (en) 1998-07-23
NZ336073A (en) 2001-01-26
CZ242699A3 (cs) 1999-11-17
JP2000509725A (ja) 2000-08-02
CA2277274C (en) 2003-05-27
TR199901578T2 (xx) 1999-09-21
DE97951771T1 (de) 2004-07-08
CA2387356A1 (en) 1998-07-23
CA2387361A1 (en) 1998-07-23
EP1077988A1 (en) 2001-02-28
JP5190350B2 (ja) 2013-04-24
CZ297433B6 (cs) 2006-12-13
AR039666A2 (es) 2005-03-02
CN1244869A (zh) 2000-02-16
JP4058114B2 (ja) 2008-03-05
JP2004075689A (ja) 2004-03-11
AU735598B2 (en) 2001-07-12
WO1998031699A1 (en) 1998-07-23
JP2009137975A (ja) 2009-06-25
AR039667A2 (es) 2005-03-02
AU5532698A (en) 1998-08-07
BR9714287A (pt) 2000-04-18

Similar Documents

Publication Publication Date Title
IL130255A0 (en) Crystal form 0 of clarithromycin
SI1445259T1 (sl) Uporaba kristalnih oblik 2-metil-tienobenzodiazepina
HK1003367A1 (en) Fastening tab
TW321414U (en) Pivot-rotation device of flat-display panel
PL338144A1 (en) Derivatives of dolastatin 15
PL340290A1 (en) 2-halogeno-6-0-substituted derivatives of ketolide
PL326604A1 (en) Derivatives of 5"-dezoxy-cytidin
IL115062A0 (en) Spirostanyl glycosidal crystals
EP0829526A4 (en) LIQUID CRYSTAL COMPOSITION
ZA968868B (en) Furnace
PL337612A1 (en) Crystalline form of roxyfiban
IL119434A0 (en) Furnace
TW342087U (en) Low temperature show case
ZA9810718B (en) Novel crystal modification of thiazine-indigo
GB2286173B (en) Anchor arrangements
GB9512832D0 (en) Bricks
EP0758191A3 (de) Deglorofen
GB9723845D0 (en) 6568471001
GB2304851B (en) Fastening devices
GB2285462B (en) Brick
KR0108798Y1 (en) Walls of elements of thin form
GB9419335D0 (en) Comforter
TW357554U (en) Improvement of shinguards
IL115554A0 (en) Earthquake-proofing of structures
GB9512104D0 (en) Refractories

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
EXP Patent expired